Tonix Pharmaceuticals Holding Earnings Call Transcripts
Fiscal Year 2026
-
TONMYA Q3 net sales rose 37% QoQ to $15M as coverage reached 53% of U.S. lives. Pipeline priorities include MDD and a Lyme antibody trial planned for 2027; Q3 cash was $163M with runway into Q3.
-
TONMYA sales and prescriptions grew in Q3 as payer access and the expanded sales force supported launch momentum. Cash plus post-quarter equity proceeds are expected to fund operations into early Q3 2027, while pipeline studies advance.
-
TONMYA's launch for fibromyalgia has shown strong early sales growth and broadening access, with a unique mechanism and favorable tolerability. The pipeline includes a phase II-ready Lyme disease antibody and an anti-CD40 ligand program for transplantation, supported by a solid cash position into 2027.
-
Recent results show strong uptake of a new fibromyalgia therapy, with net sales tripling quarter-over-quarter and expanded market access. The pipeline includes a monoclonal antibody for Lyme disease prevention entering phase II in 2025 and a phase II study for major depression, both with results expected by 2028.
-
Q2 2026 saw robust revenue growth driven by Tonmya's successful launch, expanded market access, and strong refill dynamics, while pipeline programs advanced with pivotal studies in MDD and Lyme disease prevention. Cash runway extends into early Q2 2027.
-
Achieved first-in-class approval and strong early sales for a fibromyalgia drug, with accelerating Q2 trends and broadening payer coverage. Digital marketing and a growing sales force support expansion, while a large addressable market and pipeline for Lyme disease prevention offer significant long-term potential.
-
A new fibromyalgia therapy has launched with positive early adoption and broad prescriber engagement, supported by robust patient access and a dynamic commercial strategy. The pipeline includes a promising Lyme disease prevention antibody, and financial resources are strong.
-
Tonmya, a novel sublingual treatment for fibromyalgia, launched with strong commercial focus and early sales, targeting a large unmet need and potential long COVID expansion. The pipeline includes a Lyme prophylactic, depression, and transplant programs, with major milestones expected by 2027.
Fiscal Year 2025
-
Tonmya, a new sublingual treatment for fibromyalgia, is set for imminent US launch, supported by strong clinical data and a robust commercial strategy. The pipeline includes programs in CNS, immunology, infectious disease, and rare disease, with multiple studies starting in 2024.
-
Tonmya recently received FDA approval for fibromyalgia and is being launched with a focus on providers who treat the majority of diagnosed patients. The product differentiates itself through a unique mechanism, improved tolerability, and non-opioid status, aiming to address significant unmet needs and reduce opioid reliance.
-
FDA approved Tonmya, a first-in-class, non-opioid sublingual treatment for fibromyalgia, following robust phase III trials. The company is launching with a 90-person sales force, targeting both diagnosed and undiagnosed patients, and expects commercial availability next quarter.
-
Fast Track status and a strong pipeline position the company for a major 2025 launch of TNX-102SL for fibromyalgia, supported by commercial migraine products and robust R&D. Additional programs target acute stress, cocaine intoxication, and infectious diseases.